Aselizumab, designated HuDreg-55, is a emerging monoclonal antibody engineered to bind to C1q. How it works involves interfering with the classical complement pathway, potentially offering efficacy in https://aselizumab-liquid-protei334828.blogdigy.com/aselizumab-a-in-depth-investigation-into-hudreg-55-69275064